First-in-class therapy targets 'undruggable' protein in hard-to-treat blood cancers
A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood.
A groundbreaking therapy targeting the MYC protein, a notorious "undruggable" component in numerous cancers, has shown promising results in preclinical studies by researchers at The University of Texas MD Anderson Cancer Center. The experimental drug, named GT19630, disrupts a unique relationship between MYC and a protein called GSPT1, effectively disabling a critical pathway that fuels cancer growth.
This innovative approach, which leverages the cell's natural protein recycling system, has demonstrated strong anticancer activity across various preclinical models of leukemia, lymphoma, and multiple myeloma, including those resistant to current treatments and those with TP53 mutations. By simultaneously degrading both MYC and GSPT1, GT19630 offers a novel strategy to overcome resistant cancers, potentially identifying a select group of treatment-resistant leukemia cells while minimizing harm to healthy bone marrow. Further clinical trials are necessary to assess the drug's safety and efficacy in humans.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
